Breakthrough Obesity Treatments: New Guidelines Prioritize GLP-1 Agonists

New guidelines from the European Association for the Study of Obesity prioritize GLP-1 agonists, including semaglutide and tirzepatide, as first-line treatments for obesity and its complications. Despite high costs, these drugs are deemed transformative, though they should be combined with lifestyle strategies for long-term success.

The European Association for the Study of Obesity has issued new guidelines prioritizing GLP-1 agonists like semaglutide and tirzepatide as the foremost treatments for obesity and related complications.

These medications have been highlighted for their efficacy in urgent weight-loss scenarios, with specific recommendations based on complications like sleep apnea and osteoarthritis.

While acknowledging the costs and potential side effects, experts urge integration of these drugs into treatment regimens, augmented by lifestyle modifications, to optimize patient health outcomes.

(With inputs from agencies.)